DexCom, a leading manufacturer of continuous glucose monitoring systems, is confronting one of the most significant ...
DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...
Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...
Carrot today announced a partnership with URA, the world's leading smart ring, and Dexcom, the global leader in glucose biosensing, to empower members with actionable, personalized insights that ...
The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Dexcom, Inc. securities during the class period because the Company ...
Lead Plaintiff Deadline is December 26, 2025 NEW YORK, Nov. 11, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that ...
Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month ...
A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to update the app.
EMBED <iframe src="https://archive.org/embed/monthly-ascii-1993-09" width="560" height="384" frameborder="0" webkitallowfullscreen="true" mozallowfullscreen="true ...
Truist lowered the firm’s price target on DexCom (DXCM) to $82 from $94 and keeps a Buy rating on the shares. The company’s Q3 earnings and revenue beat was modest, but its light gross margins were ...
With a new head coach and almost entirely new roster, Saturday night served as a reintroduction of sorts fpr the WVU Tech men’s basketball team. The fans seemed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback